Company profile
SYBLEU Inc
OTC: SYBE · Healthcare · Biotechnology
#1138 of 1,422 Healthcare companies by revenue41st-percentile growth
EA Score
——FH —DQ —GM —SS 14
v0.1 · 5/100 weight · pillars only
↑ Altman-Z, revenue growth (YoY) · ↓ workforce scale, listing tenure
Methodology →Revenue TTM
$11.7k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$180.3k
Employees
2
as of 2026-08-26
Market cap
$583.7k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$11.7k$11.7k2022
Net income-$180.3k-$180.3k2022
Operating income-$149.2k-$149.2k2022
Total assets$61.0k$61.0k2022
Liabilities$327.1k$327.1k2022
Equity-$266.1k-$266.1k2022
Revenue trend
FY2019 – FY2022 · USD
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is SYBLEU Inc’s revenue?
SYBLEU Inc booked $11.7k in FY2022 revenue, contracting 0.0% year over year — about the middle of the pack among Healthcare companies we track, at a -1541.6% net margin.
Peers · Healthcare
Evolutionary Genomics, Inc.——First Colombia Gold Corp.——Baseline Productions, Inc.——Modern Mobility Aids, Inc.——Voyageur Pharmaceuticals Ltd.——Genelux Corporation32DNeighbors
Bronx →Key facts
CEOJoseph G. Vaini
SectorHealthcare
IndustryBiotechnology
HeadquartersBronx, NY
ExchangeOTC: SYBE
Employees2
IPO date2023-05-30
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.